JESSE GOODMAN - 30 Jun 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
/s/ James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
30 Jun 2025
Net transactions value
-$29,068
Form type
4
Filing time
02 Jul 2025, 17:50:11 UTC
Previous filing
13 Jun 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GOODMAN JESSE Director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE /s/ James Basta, attorney-in-fact 02 Jul 2025 0001756929

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale $14,789 -1,547 -5.6% $9.56 25,906 30 Jun 2025 Direct F1
transaction NTLA Common Stock Sale $14,279 -1,547 -6% $9.23 24,359 01 Jul 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported sale of 3,094 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 31, 2025.